Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 9/20 | 0.63 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899441 | 0.83 | KAT6A (0.57) | KAT6AGBA1 | |
| SCHEMBL5899462 | 0.81 | KAT6A (0.71) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL5899477 | 0.76 | KAT6A (0.65) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL5899491 | 0.76 | KAT6A (0.62) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL5899421 | 0.76 | KAT6A (0.65) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL5899507 | 0.74 | KAT6A (0.66) | KAT6ACA12CA1CA2CA9 | |
| SCHEMBL6851861 | 0.74 | GBA1 (0.57) | KAT6AGBA1 | |
| SCHEMBL15621004 | 0.72 | GBA1 (0.55) | KAT6AGBA1 | |
| SCHEMBL5899446 | 0.72 | KAT6A (0.72) | KAT6A | |
| SCHEMBL1974978 | 0.71 | PTPN1 (0.71) | PTPN1KDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | WYETH | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | KAT6A 2440/4885CA12 2807/4885CA1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.